



---

## Overview

After the Human Genome Project was completed in 2003, early successes in genomic medicine fell short of the initial high expectations. But today, a potent mix of influences—including innovation in biology and technology, market demand and consumerism—is furthering an evolution that crosses industries.

Healthcare providers can now personalize care plans thanks to lower sequencing costs that allow genomic data to be combined with electronic health data. Life sciences companies can develop targeted therapies that prevent and alleviate disease symptoms. To capitalize on new advances in science, cognitive computing, analytics and drug discovery, senior leaders across the ecosystem should act quickly to: make genomic medicine a key component of enterprise strategy; address relevant skill gaps; and determine how partnering can bolster critical capabilities.

---

## IBM Institute for Business Value


# The evolving promise of genomic medicine

### *How advanced technologies are transforming healthcare and life sciences*

Since 2001, when the first draft of the Human Genome Project was announced, hope surged for genomic medicine to be a panacea for many health conditions from diagnosis to treatment. Soon after the project was complete in 2003, the early tangible examples of success did not match the high expectations of that time. But today, there is renewed confidence in the healthcare and life sciences industries that the hype could indeed match the hope. Consider what is different now:

- In the healthcare industry, the decreased cost of whole-genome sequencing—coupled with new advances in cognitive computing and drug discovery—has created a new paradigm where genomic data will soon be combined with electronic health data. Care providers are increasingly relying on genomic data to add a unique level of personalization to an individual's care plan. Cognitive computing and other analytics technologies can provide for precision care where decision support enables a reliable diagnosis and care plan, including treatment options.
- In the life sciences industry, the stage is set for a radical transformation. New medical and technological capabilities will increasingly lead to innovative clinical trials, the development of targeted therapies and a focus on health outcomes to prevent and alleviate disease symptoms.

We believe that genomic medicine is at a unique inflection point in medicine's history due to three major forces: *innovation in biology and technology*; *market demand*; and *consumerism*.



## Exploring major changes ahead from genomic medicine

Genomic medicine will be a “game-changer” for important stakeholders that include patients, providers, researchers, payors, diagnostic companies, policy makers, life sciences and governments. Three significant impacts are underway:


(1) The growing use of a new genomic health record. In the next three to five years, it is likely that an individual who interacts with the healthcare system will have a genome-based electronic record or “genomic health record.”

(2) Greater benefits for stakeholders in the three genomic medicine cornerstones:

- *Sequencing*—Processing raw data into usable form
- *Translational medicine*—Finding relationship between genome and phenotypes and discovering/developing treatments
- *Personalized healthcare*—Applying useful clinical insights to patients.

(3) Opportunities for radical industry transformation across healthcare and life sciences.

All of these cornerstones will work in a cloud-based model that adds new dimensions of data sharing, collaboration and efficiency (see Figure 1). As genomic medicine continues to proliferate, the importance of a solid privacy, ethical and legal framework to support the complexity of genomic medicine will also become vital.



### Cloud 3.0



Source: Adapted from IBM Global Technology Outlook, 2014.

**Figure 1: Three cornerstones of genomic medicine can operate in the cloud: sequencing, translational medicine and personalized healthcare.**

## Considerations for industry executives

A new genomic health record will become a reality as genomic information gets combined with relevant data extracted from the traditional EMR. Rapid, precision oncology decision support is expected to expand on a larger scale by performing sophisticated genome/proteome/RNA analysis coupled with cognitive computing. The capabilities and technologies associated with cognitive computing are critical to the ongoing genomic medicine evolution by enabling much more sophisticated decision support, innovative clinical trials, new targeted therapies, and a focus on health outcomes to prevent and alleviate disease symptoms.

To benefit from the far-reaching industry transformation that has begun, forward-thinking executives can: verify that genomic medicine is part of their enterprise vision and strategy; assess and plan to fill existing and future skill gaps; and look closely at how and when partnering will help their organizations succeed in meeting stakeholder needs.

---

## Key Contacts

Aditya Pai  
Aditya.pai@ca.ibm.com

Takahiko Koyama  
Koyama1@jp.ibm.com

Leonard Lee  
thirteen@us.ibm.com

Heather Fraser  
hfraser@uk.ibm.com

---

To read the full version of this paper including a detailed glossary of terms, visit

[ibm.com/services/us/gbs/thoughtleadership/genomicmedicine/](http://ibm.com/services/us/gbs/thoughtleadership/genomicmedicine/)

To learn more about this IBM Institute for Business Value study, please contact us at [iibv@us.ibm.com](mailto:iibv@us.ibm.com). For a full catalog of our research, visit:

[ibm.com/iibv](http://ibm.com/iibv)

Access IBM Institute for Business Value executive reports on your tablet by downloading the free “IBM IBV” app for [iPad](#) or [Android](#) from your app store.

Be among the first to receive the latest insights from the IBM Institute for Business Value. Subscribe to IdeaWatch, a monthly e-newsletter featuring executive reports that offer strategic insights and recommendations based on our research: [ibm.com/gbs/ideawatch/subscribe](http://ibm.com/gbs/ideawatch/subscribe)

---

## How can IBM help?

IBM Healthcare and Life Sciences is creating a smarter, more connected healthcare system that delivers better care and empowers people to make better choices. In addition to the company’s investment in health technology research and innovation, IBM’s healthcare solutions and consulting enable organizations to achieve greater efficiency within their operations, collaborate to improve outcomes, and integrate with new partners for a more sustainable, personalized and patient-centric system focused on value.

---



---

© Copyright IBM Corporation 2014

IBM Global Services  
Route 100  
Somers, NY 10589  
U.S.A.

Produced in the United States of America  
July 2014  
All Rights Reserved

IBM, the IBM logo and [ibm.com](http://ibm.com) are trademarks or registered trademarks of International Business Machines Corporation in the United States, other countries, or both. If these and other IBM trademarked terms are marked on their first occurrence in this information with a trademark symbol (® or ™), these symbols indicate U.S. registered or common law trademarks owned by IBM at the time this information was published. Such trademarks may also be registered or common law trademarks in other countries. A current list of IBM trademarks is available on the Web at “Copyright and trademark information” at [ibm.com/legal/copytrade.shtml](http://ibm.com/legal/copytrade.shtml)

Other company, product and service names may be trademarks or service marks of others.

References in this publication to IBM products and services do not imply that IBM intends to make them available in all countries in which IBM operates.

This report is intended for general guidance only. It is not intended to be a substitute for detailed research or the exercise of professional judgment. IBM shall not be responsible for any loss whatsoever sustained by any organization or person who relies on this publication.

The data used in this report may be derived from third-party sources and IBM does not independently verify, validate or audit such data. The results from the use of such data are provided on an “as is” basis and IBM makes no representations or warranties, express or implied..



Please Recycle